Administration of CXCL5 neutralizing antibody at 10 μg/mL doses increased the protein expression of VEGF and SDF-1 in HG-stimulated EPCs from non-DM subjects (Fig. 2C). This evidence concerns the gene CXCL12 and diabetes mellitus.